2016 Fiscal Year Final Research Report
Development of molecular-targeted therapeutic agent targeting novel platelet activation receptor CLEC-2
| Project/Area Number |
15K19549
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
SHIRAI Toshiaki
TSUKIJI Nagaharu
SHINMORI Hedeyuki
INOUE Katsue
OZAKI Yukio
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Keywords | 血小板 / CLEC-2 / ロドサイチン |
|---|
| Outline of Final Research Achievements |
Platelet activation receptor CLEC-2 binds to podoplanin expressed on the surface of several kinds of cancer cells, which facilitates cancer metastasis. Therefore, anti-CLEC-2 drugs are expected to have anti-platelet and anti-metastatic effects. We focused on snake venom rhodocytin as its drug discovery source. In order to verify the binding site of rhodocytin with CLEC-2 and the formation mechanism of the complex, recombinant wild-type and mutant rhodocytin were produced with mammalian cell line. As a result, we found mutant rhodocytin with anti-CLEC-2 effect. In the mouse model, this mutant rhodocytin strongly inhibited podoplanin-dependent cancer metastasis without inducing platelet aggregation.
|
| Free Research Field |
血栓・止血学
|
